MT-3921 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
26HTLV-1-associated myelopathy1

26. HTLV-1-associated myelopathy


Clinical trials : 28 Drugs : 48 - (DrugBank : 28) / Drug target genes : 38 - Drug target pathways : 127
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05240612
(ClinicalTrials.gov)
March 202213/2/2022A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM)HTLV-1-Associated Myelopathy (HAM)Biological: MT-3921;Biological: PlaceboMitsubishi Tanabe Pharma CorporationNULLNot yet recruiting20 YearsN/AAll15Phase 1NULL